Hackers have been exploiting an Adobe Reader zero-day vulnerability since December 2025; PDF users are warned.

A critical Adobe Acrobat zero-day has been exploited for months via malicious PDFs to steal data and potentially take over ...

Want to correct errors or update content in a PDF? Whether you prefer a powerful, corporate-friendly solution or a basic app you can use at no cost, we're here to help you find the right PDF software ...

Eli Lilly's GLP-1 drugs have seen strong demand, which has investors excited about the future. The company knows that its GLP-1 success won't last forever and is exploring additional paths. Eli Lilly ...

Tried fixing a tiny typo in your NotebookLM slides, only to realize you can’t? The PDF NotebookLM generates aren’t made of neat, editable text boxes. They’re layered images, which you can’t edit. So ...

Java ranked third in the Tiobe Index for January 2026 at 8.71%, holding steady behind Python and C and just ahead of C++. Tiobe named C# its Programming Language of the Year for 2025 after the largest ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Gene editing has the potential to cure thousands of people suffering from devastating rare diseases. But the Nobel Prize-winning technology faces a basic math problem: It’s not profitable to spend ...

Enterprise Java platform Azul Systems Inc. today announced the acquisition of Payara Services Ltd., a global enterprise-grade provider of Java applications and microservices, to expand the company’s ...

For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient ...

For a director like Guillermo del Toro, you can only imagine what he’ll do when he gets to create his fantasy project. With Frankenstein, Del Toro and his crew of craft collaborators were finally able ...

Regeneron Pharmaceuticals is committing $150 million to begin an alliance on a Tessera Therapeutics gene-editing medicine nearing the clinic as a potential treatment for a rare disease that leads to ...